Grifols (GRF) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
The annual meeting is scheduled for April 16, 2026, to elect three directors and ratify the selection of the independent auditor for the year ending December 31, 2026.
Shareholders of record as of February 20, 2026, are entitled to vote, with one vote per share and no cumulative voting rights.
Proxies will be voted in accordance with shareholder instructions, and may be revoked at any time before the meeting.
Voting matters and shareholder proposals
Proposal 1: Election of three directors (Class I) for three-year terms; nominees are Jason W. Allen, Robert M. Bilkie, Jr., and Phillip J. Hanrahan.
Proposal 2: Ratification of Cohen & Company, Ltd as independent registered public accountants for 2026.
Shareholder proposals for the 2027 meeting must be received by November 14, 2026, to be considered for inclusion.
Board of directors and corporate governance
The board is divided into three classes with staggered terms; current nominees and continuing directors have diverse backgrounds in law, finance, and investment.
The Chairman and CEO roles are separated; the Chairman is not an Interested Person.
The board has only one standing committee, the Audit Committee; there are no nominating or compensation committees.
All directors attended at least 75% of board and committee meetings in 2025.
Shareholders may communicate with the board via the Secretary; no formal policy for director nominations by shareholders.
Latest events from Grifols
- Revenue up 2.6% to €3.57bn, net profit €227m, margin 23.9%, Biopharma drives growth.GRF
Q2 2026 - Q1 2026 saw Biopharma-led growth, margin stability, and improved financial flexibility.GRF
Q1 2026 - Net profit more than doubled and revenues rose 7%, driven by Biopharma and IG growth.GRF
Q4 2025 - Q3 profit surged over 245% with strong Biopharma growth and improved leverage.GRF
Q3 2025 - Q3 revenue up 12.4%, margins and cash flow improved, leverage down after SRAAS sale.GRF
Q3 2024 - Q2 revenue up 9.3% cc, H1 EBITDA up 24.1%, net profit €36.3M, leverage at 5.5x.GRF
Q2 2024 - Aims to double revenue to €14 billion by 2034 through Biopharma growth and innovation.GRF
CMD 2025 - Record Q1 2025 results with strong growth, margin gains, and improved leverage.GRF
Q1 2025 - Record 2024 revenue, profit, and cash flow, with improved leverage and Biopharma growth.GRF
Q4 2024